The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The product is expected to be launched in Q3FY25
The observations are of procedural in nature and will be responded to within the stipulated time
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Developed in consultation with clinicians and patients for an enhanced user experience
Potential of Ayurveda’s contribution in global health system through various innovative practices
Subscribe To Our Newsletter & Stay Updated
